The compnay claims that Maris Plus stent features an exclusive cell design at the stent ends. This allows physicians to place several stents in series without stiffening the artery in the overlap region. The Maris Plus is the sixth stent platform now marketed by Invatec for the treatment of peripheral arterial disease (PAD).
Stefan Widensohler and Andrea Venturelli, co-founders of Invatec, said: “It was our goal to offer dedicated stent geometries to respond to the different needs of the iliac and SFA arteries. With the Maris Plus, we have created a stent with an overlap region that allows two stents to act like one in the femoral artery.”